PMPRB releases new Guidelines to monitor and review drug prices

Imported from official source

Announcement

Safety Classified by Officially

PMPRB releases new Guidelines to monitor and review drug prices

June 30, 2025 — Ottawa, ON — Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (PMPRB) published its new Guidelines for PMPRB Staff today. They will take effect on January 1, 2026. The Guidelines explain the new two-step process used by PMPRB staff to monitor and review drug prices by comparing them to the prices in other countries or to other similar treatments in Canada. If a drug's price raises concerns, PMPRB staff may recommend a hearing to the Chair. These new Guidelines have been established following a comprehensive consultation process, after much consideration from the Board. They depart significantly from previous Guidelines.

As per the new Guidelines, the PMPRB will follow a two-step review process. The Initial or Annual Review serves as a screening process. If this step raises concerns, or if a complaint is received from an approved individual or organization, the PMPRB will then start a more in-depth review. During an In-Depth Review the PMPRB staff compare the drug under review to similar drugs and treatments available for the same medical conditions.

The PMPRB plays a unique and important role in the Canadian health system by ensuring that prices of patented medicines are not excessive. The Guidelines provide a transparent and predictable process to be used by PMPRB staff to review drug prices once they enter the market. 

The PMPRB protects consumers by ensuring that the prices of patented medicines in Canada are not excessive and reports on pricing trends.

The PMPRB does not set drug prices in Canada. The PMPRB reviews prices to ensure that Canadian prices are not excessive.

If an in-depth review indicates that the drug could be priced excessively in Canada, PMPRB staff can recommend a hearing to the Chairperson. If a hearing panel determines the price is excessive, they may order a price reduction.

This is an extract. The publication continues at the source.

Source: Patented Medicine Prices Review Board. Licence

Read the original at the source: https://www.canada.ca/en/patented-medicine-prices-review/news/2025/06/pmprb-releases-new-guidelines-to-monitor-and-review-drug-prices.html

Officially imported this from Patented Medicine Prices Review Board’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
Patented Medicine Prices Review Board — imported from official source
Official source
https://api.io.canada.ca/io-server/gc/news/en/v2?dept=patentedmedicinepricesreviewboard&sort=publishedDate&orderBy=desc&publishedDate%3E=2021-07-23&pick=50&format=atom&atomtitle=Patented%20Medicine%20Prices%20Review%20Board ATOM
Imported
October 03, 2026 20:43
Versions
1 recorded
Identity
https://www.canada.ca/en/patented-medicine-prices-review/news/2025/06/pmprb-releases-ne...

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.